Table 1.
List of monoclonal antibodies approved for targeted therapy in breast cancer.
| Approved Agents | Molecular Targets | Mechanism of Action | Ref. | |
|---|---|---|---|---|
| Trastuzumab (Herceptin®) |
HER-2, HER-3 | RAS/Raf/MAPK Inhibition | [20,21,22,23,24,25,26,27,28,29,30,31,32,33] | |
| Pertuzumab (Perjeta®) |
EGFR y HER-4 | [26,32,53,54] | ||
| Monoclonal antibody | Bevacizumab (Avastin®) |
VEGF | VEGFR PI3K, PLCγ prevents neovascularization |
[34,35,36,37,38,39] |
| [34,35] | ||||
| [55] | ||||
| Ranibizumab (Lucentis®) | ||||
| Aflibercept (Zaltrap®) | ||||
| Cetuximab (Erbitux®) |
EGFR | PI3K, RAS, STAT signaling inhibition | [43,44,45,46,47,48,50,56] | |
| Panitumumab (Vectibix®) |
[49,50,51,52] | |||
| Antibody-drug conjugate | T-DM1 (Trastuzumab emtansine) |
HER-2 | Cytotoxic agent vinca alkaloid | [26,27,57] |
| Vinorelbine (Navelbine®) Trastuzumab (Herceptin®) |
RAS/Raf/MAPK | [58] | ||
| Sacituzumab govitecan-hziy | antibody-drug targeting trophoblast cell surface antigen 2 | [59] |